Loading company…
Novaliq GmbH is a Heidelberg biotechnology firm developing ophthalmic and dermatological therapies using its drug delivery technology.
Founded in 2007 in Heidelberg, Germany, Novaliq GmbH focuses on advanced drug delivery for ophthalmology and dermatology. It has secured a total of USD 53 mn through four deals, the latest in October 2018 led by Dievini, and was valued at approximately USD 142.99 mn at its most recent round. Its current CEOs are Christian Roesky and Frank Löscher, and it reported revenue of USD 7.81 mn for fiscal 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in